جست‌وجوی استاد و پژوهشگر

Todd Przybycienمشاهده پروفایل

استاد

• Bioprocess Engineering
• Vaccine Development
• Protein Purification
• +۳ مورد دیگر

Todd Przybycien is a Professor in the Department of Chemical and Biological Engineering at Rensselaer Polytechnic Institute. His research focuses on bioprocess engineering, with emphasis on continuous manufacturing processes for biopharmaceuticals, protein purification technologies, and vaccine development. He leads efforts in optimizing downstream processing for monoclonal antibodies and mRNA vaccines through precipitation and filtration systems. His work integrates computational modeling (e.g., population balance models in CADET) with experimental validation. Key research areas include: Continuous downstream processing mRNA vaccine purification via affinity membranes Precipitation-based capture technologies Laser force cytology for viral potency analysis Przybycien collaborates on projects funded through industry partnerships and NSF GOALI grants, emphasizing smart manufacturing concepts in biomanufacturing. He has co-authored over 100 publications in top journals like Biotechnology and Bioengineering and Separation and Purification Technology.

• Nanomedicine
• Lipid Nanoparticles
• RNA Therapeutics
• +۲ مورد دیگر

Pieter Cullis is a Professor at the University of British Columbia's Department of Biochemistry and Molecular Biology, Faculty of Medicine. He directs the Nanomedicine Research Group from the Life Sciences Centre office 5451. His research focuses on membrane structure/function relationships and therapeutic applications of lipid nanoparticles (LN). Key areas include: LN delivery systems for siRNA and genetic drugs Immunostimulatory drug delivery for cancer therapy Chemotherapeutic encapsulation for tumor-targeted delivery His work has led to clinical-stage liposomal formulations including a doxorubicin treatment currently in advanced trials. Publications demonstrate consistent focus on lipid nanoparticle evolution, with recent advancements in mRNA transfection potency and in vivo CAR T cell engineering. Research trends show progression from fundamental lipid design to clinical translation of nucleic acid therapeutics.

Myles Akabasمشاهده پروفایل

استاد

• Malaria Parasite Physiology
• Drug Transport Mechanisms
• Antimalarial Drug Development
• +۳ مورد دیگر

Myles Akabas, M.D., Ph.D., is a Professor in the Dominick P. Purpura Department of Neuroscience and the Department of Medicine at Albert Einstein College of Medicine. He also serves as Director of the Medical Scientist Training Program (MSTP), supported by the George Y. and Catherine H. Wu MSTP Directorship. His research focuses on malaria parasite physiology, particularly purine and phosphate transport mechanisms, with a goal of developing novel antimalarial drugs targeting transporters like PfENT1. He has pioneered yeast-based high-throughput screening to identify inhibitors of these transporters, leading to promising drug candidates. Dr. Akabas’ work spans drug discovery and physician-scientist training. He co-authored studies on the outcomes of MD-PhD programs, emphasizing sociodemographic factors and training durations. His lab investigates PfENT1’s role in parasite survival and collaborates with industry partners like GSK to advance drug candidates. He has published extensively on malaria biology, transporter mechanisms, and medical education policies. His research highlights include identifying 171 PfENT1 inhibitors from a 65,000-compound screen, developing hit-to-lead compounds with improved potency, and analyzing field isolate mutations affecting drug efficacy. He also addresses systemic challenges in physician-scientist training, advocating for streamlined pathways and diversity initiatives. Dr. Akabas’ roles in MSTP leadership ensure interdisciplinary training for future physician-scientists. His labs at the Jack and Pearl Resnick Campus in the Ullmann Building focus on malaria drug development and translational research, bridging basic science and clinical impact.

Abhinandan Chowdhuryمشاهده پروفایل

پژوهشگر

• Toxicology
• Venom Research
• Bioanalytical Techniques
• +۲ مورد دیگر

Abhinandan Chowdhury is a Researcher at The University of Queensland's School of Biological Sciences, specializing in venom toxicology and therapeutic development. His work focuses on small molecule enzyme inhibitors to neutralize snake venom effects, supported by industry collaborations like Ophirex. He employs advanced bioanalytical techniques including Electric Cell-substrate Impedance Sensing (ECIS), StarMax Coagulation Analyzer, and Thromboelastography (TEG 5000) under Good Laboratory Practices (GLP) standards. Education: PhD in Biological Sciences, The University of Queensland (2023) Research Focus: Dr. Chowdhury investigates venom-induced coagulopathies and neurotoxic mechanisms across global snake species, with emphasis on enzyme inhibitor therapeutics (e.g., varespladib). His research bridges academic discovery and clinical translation, utilizing cellular models and human plasma assays to develop complementary treatments for antivenom limitations. Publication Trends: Analysis of his 15 most recent publications (2021-2025) reveals consistent focus on venom coagulotoxicity and inhibitor efficacy across viperid/elapid species. Key themes include ontogenetic venom variation, taxon-selective pathophysiology, and cross-species antivenom neutralization challenges, predominantly targeting African, Australian, and Palearctic snakes. Research Leadership: He manages complex laboratory operations, mentors students, and directs instrumentation for high-throughput venom analysis. His industry partnerships demonstrate commitment to translating biochemical findings into real-world snakebite solutions, particularly through small molecule therapeutic development.

Bryan Grieg Fryمشاهده پروفایل

استاد

• Venom evolution
• Toxinology
• Molecular evolution
• +۶ مورد دیگر

Professor Bryan Grieg Fry is a Professor at the School of the Environment, Faculty of Science, University of Queensland, and an Affiliate of the Centre for Marine Science. With over two decades of research experience, he leads the Adaptive Biotoxicology Lab focusing on venom evolution and toxinology. His work spans interdisciplinary approaches integrating ecology, evolution, and functional genomics to understand venom systems across diverse animal taxa. Professor Fry earned his PhD from the University of Queensland in 2002 after completing dual undergraduate degrees in Molecular Biology and Scientific Philosophy from Portland State University. His academic journey has taken him to conduct field research in over 40 countries, from Norway to Antarctica, earning him induction into The Explorers Club. Dr. Fry's research focuses on the evolution of venom systems across the animal kingdom, with particular expertise in snake, lizard, and marine animal venoms. His work ranges from discovering the shock-inducing hypotensive and anticoagulant venom of the Komodo Dragon to exploring temperature-specific adaptations of Antarctic octopus venoms. He investigates how venom composition relates to ecological roles in predation, defense, and competitor deterrence, with emphasis on coagulotoxic and neurotoxic mechanisms. Analysis of his recent publications reveals strong trends in venom variation research, particularly ontogenetic and geographic differences in venom composition and activity. His work increasingly focuses on practical applications including antivenom development and therapeutic potential of venom components. The research spans multiple disciplines including molecular evolution, hematology, neuroscience, and pharmacology. Inducted into The Explorers Club for hazardous field research in over 40 countries Featured in over 100 documentaries across major networks including BBC, Discovery Channel, and National Geographic Professor Fry has supervised numerous PhD students to completion, with current supervision focusing on scorpion pathophysiology, American pit viper venom variation, and anaconda ecology. His research has been supported by multiple ARC Discovery Projects, including current funding for 'Evolutionary models and biodiscovery tools from neurotoxic snake venoms' (2021-2024) and 'Functional evolution and therapeutic potential of snake venom coagulotoxins' (2019-2022). He directs the Adaptive Biotoxicology Lab, which employs interdisciplinary approaches combining molecular biology, biochemistry, and evolutionary analysis. The lab has developed innovative methods for venom characterization and has made significant contributions to understanding venom resistance mechanisms in prey species.

Fiona Thomsonمشاهده پروفایل

استاد

• Cancer Research
• Biomarker Development
• Clinical Trials
• +۳ مورد دیگر

Fiona Thomson is an Honorary Professor in the School of Cancer Sciences at the University of Glasgow and serves as Director/Senior Research Fellow of the Translational Pharmacology Laboratory (TPL). Her research focuses on translating novel anti-cancer therapies into clinical practice, with an emphasis on biomarker discovery and molecular profiling to improve personalized treatments. She collaborates closely with the Glasgow Experimental Cancer Medicine Centre (ECMC) and the Beatson West of Scotland Cancer Centre. Her work involves biomarker development for early-phase oncology trials and optimizing pharmacodynamic assessments using tumor and blood samples. The TPL has been recognized as a CRUK Centre of Biomarker Excellence. Key research interests include clinical trial design, precision oncology, and drug efficacy monitoring. Recent publications highlight advancements in biomarker-driven approaches, electrochemical sensing technologies for tumor mutations, and combination therapies in oncology. Grants include support from Cancer Research UK, Chief Scientist Office, and NHS Greater Glasgow and Clyde for projects such as the TASTER CML trial and PARADIGM-2 glioblastoma study.

Leslie Babonisمشاهده پروفایل

استادیار

• evolutionary development (Evo-Devo)
• origin of novelty
• invertebrate biodiversity
• +۷ مورد دیگر

Leslie Babonis is an Assistant Professor in the Department of Ecology and Evolutionary Biology at Cornell University, affiliated with the College of Arts and Sciences. Her research focuses on the mechanisms underlying the evolution of novel traits, particularly in cnidarians and ctenophores. She leads the Babonis Lab, which investigates gene regulation, cell identity, and tissue morphogenesis in organisms like corals, jellyfish, and comb jellies. Her work bridges evolutionary developmental biology and genetics, emphasizing the origins of biodiversity through studies of cell type innovation and loss. Education: Ph.D., University of Florida (2011); B.S., University of Miami (2003). Research Interests: Evolutionary development (Evo-Devo), origin of novelty, invertebrate biodiversity, cnidarians, ctenophores, gene regulation, cell identity, tissue morphogenesis, regeneration, and the evolution of multicellularity. The lab employs CRISPR, RNA sequencing, and behavioral assays to dissect these processes. Students and Advising: Advises PhD students Sarah Arnold, Kennedy Bolstad, Yareli Alvarez, and Moey Rojas, as well as undergraduate researchers like Ice. Recent accolades include NSF GRFP and NSERC grants for her advisees. Labs and Teams: The Babonis Lab operates in Corson Hall, focusing on cnidocyte evolution, colloblast gene functions, and assisted coral evolution. Collaborative projects include studies on comb jellies and sea anemones, with a particular emphasis on regeneration and defensive structures.

Luke J. Mortensenمشاهده پروفایل

استادیار

• Cellular Therapeutics
• Regenerative Medicine
• Multiphoton Microscopy
• +۳ مورد دیگر

Luke J. Mortensen is an Assistant Professor at the University of Georgia, holding a joint appointment in the College of Agricultural and Environmental Sciences' Department of Animal and Dairy Science and the Regenerative Bioscience Center. His research focuses on developing next-generation cellular therapeutics and advanced imaging techniques to study musculoskeletal health and disease. He specializes in multiphoton microscopy, stem cell biology, and lipidomics, with applications in regenerative medicine and musculoskeletal disorders. Dr. Mortensen's work involves integrating imaging modalities with lipidomic analysis to evaluate mesenchymal stromal cell (MSC) potency, particularly in contexts like hypophosphatasia and volumetric muscle loss. His projects also explore novel contrast agents (e.g., perovskites) for in vivo imaging and adaptive optics to enhance deep-tissue visualization through bone. Recent studies address collagen organization defects, pro-regenerative inflammation, and mitochondrial dynamics in injured tissues. His research trends emphasize precision medicine approaches, combining engineering solutions (e.g., bioreactors for tendon tissue engineering) with molecular insights into immune modulation and tissue repair. Collaboration with the Regenerative Bioscience Center underscores his commitment to translational applications of stem cell therapies. No scientific awards are explicitly listed in the provided texts. His work is supported by grants focused on imaging technology development and regenerative medicine. He advises students in interdisciplinary projects at the intersection of engineering and biomedical sciences. Luke J. Mortensen is based at the iSTEM 1 facility, Room 2040G, in Athens, Georgia.

• Coordination chemistry
• organic chemistry

Dr. Jelena M. Poljarević serves as an Assistant Professor in the Department of General and Inorganic Chemistry at the Faculty of Chemistry, University of Belgrade. She has been affiliated with the institution since 2008, progressing from Teaching Assistant to Assistant Professor in 2018. Her academic foundation was built entirely at the University of Belgrade through undergraduate and doctoral studies in Chemical Sciences. Her educational background includes: Undergraduate studies (2002-2007) in Chemical Sciences at the University of Belgrade - Faculty of Chemistry Doctoral studies (2007-2015) in Chemical Sciences at the University of Belgrade - Faculty of Chemistry Dr. Poljarević's research centers on Coordination Chemistry and Organic Chemistry , with emphasis on synthesizing metal complexes for biological applications. Her work explores ruthenium and rhodium organometallics for antimicrobial and antitumor properties, alongside detailed solution chemistry and structural analysis of coordination compounds. Analysis of her 14 publications (2018-2023) reveals consistent innovation in metal-based therapeutics, particularly ruthenium complexes with picolinate ligands. Key trends include antimicrobial potency testing, antitumor activity evaluation, and structure-activity relationship studies, demonstrating interdisciplinary collaboration between inorganic synthesis and biological testing. Her scientific recognition includes: 2016 Postdoctoral Scholarship from the Ministry of Education, Science and Technological Development of the Republic of Serbia Dr. Poljarević actively contributes to research projects including the current "Pioneering innovation of baby wet wipes" (2020-2021) funded by the Innovation Fund of Serbia, and the completed "Rational design of biologically active compounds" (2011) funded by the Ministry of Science. Her teaching portfolio spans General Chemistry Practicum and specialized courses in medicinal inorganic chemistry, reflecting her commitment to academic development. She maintains affiliations with the Department of General and Inorganic Chemistry, HF Innovation Center, and has been a member of the Serbian Chemical Society since 2008, contributing to the broader chemical research community.

• Toxicology
• Environmental Health
• Aryl Hydrocarbon Receptor (AhR) signaling
• +۳ مورد دیگر

Karin van Ede is a Visiting Researcher at the Faculty of Veterinary Medicine at Utrecht University . Her work focuses on toxicology and environmental health , particularly the effects of dioxin-like compounds and polychlorinated biphenyls (PCBs) on human and rodent systems. She is affiliated with the Education Centre within the Faculty. Specializes in AhR-mediated toxicity and systemic relative effect potencies Conducts comparative studies across species (human, rat, mouse) and tissues Active in computational modeling and QSAR development for pollutant risk assessment Participates in international conferences like Dioxin 2013 (Korea) and Dioxin 2010 Her research utilizes both in vitro and in silico approaches to improve human-specific risk assessment of environmental pollutants. She has extensive publication history focused on toxic equivalency factors (TEFs) and cytochrome P450 gene expression as biomarkers. Contact: k.i.vanede@uu.nl | Location: Jeannette Donker-Voetgebouw, Yalelaan 104-106, 3584 CM Utrecht

Kevan Shokatمشاهده پروفایل

استاد

• Bioorganic Chemistry
• Signal Transduction
• Protein Kinases
• +۵ مورد دیگر

Kevan Shokat is a Professor of Chemistry and Co-Chair of the Department of Cellular and Molecular Pharmacology at the University of California, San Francisco (UCSF). He previously held faculty positions at Princeton University as an Assistant and Associate Professor of Chemistry. B.A. from Reed College (1986) Ph.D. from UC Berkeley (1991) Life Sciences Research Foundation Fellow at Stanford University (1991-94) His research merges bio-organic chemistry and pharmacology to decode signal transduction pathways using chemical genetics . The Shokat Lab focuses on engineering protein kinases to develop small-molecule inhibitors for therapeutic targeting in diseases like cancer, asthma, neurological disorders, and bacterial infections. Their proprietary pyrazolopyrimidine-based system allows selective inhibition of mutant kinases with NSF Early Career Development Award (1995-97) Pew Scholar in the Biomedical Sciences (1996-00) Searle Scholar (1997-00) Cottrell Scholar (1997-00) Glaxo-Wellcome Scholar in Organic Chemistry (1997-98) Alfred P. Sloan Research Fellow (1999-2001) The lab has demonstrated applications in yeast kinases (CDC28, Fus3, Ipl1, CDC15, Cla4, Elm1, Ark1) and aims to extend this approach to C. elegans and Drosophila models. The pyrazolopyrimidine inhibitors exhibit excellent pharmacokinetic properties, including blood-brain barrier penetration and bioavailability in mice.

Guido Ferrariمشاهده پروفایل

استاد

• HIV Immunology
• Antibody-dependent cellular cytotoxicity (ADCC)
• Cytotoxic T cell responses
• +۳ مورد دیگر

Guido Ferrari is a Professor in the Department of Surgery and Research Professor in Molecular Genetics and Microbiology at Duke University School of Medicine, with affiliate status at the Duke Global Health Institute. His work focuses on HIV immunology and vaccine development, particularly in South African contexts through the Infectious Diseases in Africa initiative. His educational background includes an M.D. from the University of Genoa (1985), along with significant appointments at the University of Cape Town as Adjunct Visiting Professor (2012-2019) and Honorary Professor (2019-2024). M.D., University of Genoa (1985) Adjunct Visiting Professor, University of Cape Town (2012-2019) Honorary Professor, University of Cape Town (2019-2024) Dr. Ferrari's research centers on HIV-1 immune responses, specializing in antibody-dependent cellular cytotoxicity (ADCC) and cytotoxic T cell mechanisms. His laboratory investigates how these responses eliminate HIV-infected cells and can be harnessed for vaccine design, with continuous NIH and Gates Foundation funding over 11 years. Current projects measure immune responses in resource-limited settings and mentor young investigators fighting AIDS, tuberculosis, and malaria. His 2025 publications reveal dominant themes in HIV vaccine engineering, including neutralizing antibody development, B/T cell response dynamics in primates, and co-infection immunology with SARS-CoV-2. The work emphasizes computational vaccine design, Fc receptor functionality, and cross-protective immunity through international collaborations. No specific scientific awards are mentioned in the provided text. Dr. Ferrari actively mentors researchers in limited-resource countries through NIH/IAS initiatives. His laboratory secures substantial funding from: National Institutes of Health (Nonhuman Primate Core, EQAPOL, Multivalent mRNA HIV vaccine) Fred Hutchinson Cancer Center (HVTN Lab Center) Wistar Institute (DNA immunogen development) CRDF Global (India-Duke training exchange) He directs the CFAR Immunology Core and ADCC laboratories for HVTN/CAVD/PAVEG at Duke, operating the Innate and Adaptive Cellular Cytotoxicity Laboratory. His team coordinates international ELISpot/ICS technology transfer workshops and investigates gene expression in NK/T cells during HIV infection, with expanded focus on vaccine-induced immune ontogeny.

• Glycovirology
• Structural Biology
• Medical Virology
• +۳ مورد دیگر

Dr. Larissa Dirr is an NHMRC Early Career Fellow and Early Career Research Leader at Griffith University's Institute for Biomedicine and Glycomics. Her research focuses on glycovirology and structural biology, particularly viral and bacterial glycoproteins' roles in host-pathogen interactions. She holds a PhD from Griffith University (2016) and prior degrees in Pharmacy from Saarland University (Germany) and UC San Diego (USA). Her work combines glycobiology, molecular biology, and virology to design antiviral inhibitors. Notable contributions include co-inventor patents for anti-parainfluenza drugs and a pre-clinical licensing deal with Grand Medical Pty Ltd. She has secured funding from NHMRC, ARC, Queensland Government, and the Cumming Global Centre for Pandemic Therapeutics. Research Trends: Recent articles emphasize viral glycome remodeling, bacterial enzyme function, and drug repurposing for human metapneumovirus. Awards: 2019 NHMRC Peter Doherty Fellowship; 2025 Australian Glycoscience Society ECR Award. Grants include leadership on an NHMRC project studying viral glycosylation hijacking and an ARC-funded study on erythropoiesis protein glycosylation. She serves as an editorial board member for Antiviral Research and is an executive member of the Queensland Protein Group.

• Virology
• Antiviral Drug Development
• Vaccine Research
• +۳ مورد دیگر

Johan Neyts is a full professor at KU Leuven's Faculty of Medicine and heads the Virology, Antiviral Drug & Vaccine Research Group, the Division Virusbank, and other research subdivisions. He specializes in antiviral drug development, virology, and pandemic preparedness, with a focus on coronaviruses, flaviviruses, and hepatitis viruses. His research integrates molecular biology, drug discovery, and translational medicine. Research interests include viral pathogenesis, antiviral mechanisms, and vaccine design. He leads projects like the European Viral Outbreak Response Alliance and develops broad-spectrum antivirals for pandemic threats. He is also involved in preclinical and clinical studies of antiviral candidates targeting SARS-CoV-2, dengue, and hepatitis viruses. Notable contributions include discovering inhibitors for norovirus, SARS-CoV-2 membrane protein, and hepatitis E virus. His work emphasizes translational research to bridge basic science and clinical applications.

Inigo Zubiavrre Martinezمشاهده پروفایل

استاد

• Cancer Biology
• Tumor Immunology
• Radiotherapy
• +۳ مورد دیگر

Inigo Zubiavrre Martinez is a Professor in Cell Biology at the Department of Clinical Medicine, UiT The Arctic University of Norway in Tromsø. He serves as the Group Leader for the Molecular Inflammation Research Group (MIIIRG-IKM) with over 20 years of academic experience in cancer research and teaching. His work focuses on tumor microenvironment dynamics, particularly cancer-associated fibroblasts (CAFs), and their role in modulating responses to radiotherapy and immunotherapy. Research Focus: Professor Martinez investigates the immunoregulatory functions of CAFs in tumor progression, radiation resistance, and immunosuppression. Key areas include: Radiation-induced changes in CAF signaling pathways (TGF-β/PDGF) Extracellular vesicle-mediated communication in irradiated tumors PET-imaging biomarkers for monitoring CAF responses ( e.g., FAPI-74 tracers) Combinatorial radio-immunotherapy strategies to overcome therapeutic resistance Publication Trends: Recent articles demonstrate a strong focus on molecular mechanisms of tumor stroma interactions with radiation/immunotherapy, utilizing proteomics, transcriptomics, and novel imaging techniques. Work frequently involves preclinical models to validate clinical translation potential. Collaborations & Leadership: Leads multidisciplinary teams developing immuno-PET tracers and exploring proton therapy applications. Coordinates projects on radiation-induced immune modulation across European institutions.